Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein

Abstract Background Sarcomas comprise a heterogeneous group of aggressive mesenchymal malignancies with limited therapeutic options and poor prognosis, underscoring the need for novel treatment strategies. Fibroblast activation protein (FAP), which is highly expressed on sarcoma-associated fibroblas...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jing-Ren Tseng, Cheng-Lung Hsu, Hsin-Hua Hsieh, Kung-Chu Ho, Chun-Yi Wu, Ko-Han Lin, Yi-Hsiu Chung, Chi-Chang Weng
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	SpringerOpen 2026-03-01
Sarja:	EJNMMI Research
Aiheet:	Sarcoma Fibroblast activation protein Radioligand therapy [177Lu]Lu-FAPI-2286 [18F]F-FAPI-74 Tyrosine kinase inhibition
Linkit:	https://doi.org/10.1186/s13550-026-01405-z
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!